Latest & greatest articles for cancer

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on cancer or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on cancer and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for cancer

8601. Use of In-111 Capromab Pendetide in detecting metastatic prostate cancer

Use of In-111 Capromab Pendetide in detecting metastatic prostate cancer Use of In-111 Capromab Pendetide in detecting metastatic prostate cancer Use of In-111 Capromab Pendetide in detecting metastatic prostate cancer Howell T, Hailey D Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Howell T, Hailey D. Use of In-111 Capromab Pendetide (...) in detecting metastatic prostate cancer. Edmonton: Alberta Heritage Foundation for Medical Research (AHFMR). HTB-5. 1999 Authors' objectives To summarise the effectiveness and cost-effectiveness of In-111 Capromab Pendetide in detecting metastatic prostate cancer. Authors' conclusions Imaging with In-111 Capromab Pendetide provides an additional method for detection of metastatic disease in prostate cancer. As the images are difficult to interpret, it would be essential for clinicians to receive

Health Technology Assessment (HTA) Database.1999

8602. The early detection and diagnosis of breast cancer: a literature review - an update

The early detection and diagnosis of breast cancer: a literature review - an update The early detection and diagnosis of breast cancer: a literature review - an update The early detection and diagnosis of breast cancer: a literature review - an update New Zealand Health Technology Assessment Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation (...) New Zealand Health Technology Assessment. The early detection and diagnosis of breast cancer: a literature review - an update. Christchurch: New Zealand Health Technology Assessment (NZHTA) 1999 Authors' objectives This review was commissioned by the Royal New Zealand College of General Practitioners and was primarily intended to update a previous report undertaken by Drs Pullon and MacLeod in 1996. Authors' conclusions Most of the findings in this review were either consistent with those

Health Technology Assessment (HTA) Database.1999

8603. Screening for prostate cancer, Norwegian review of international studies

Screening for prostate cancer, Norwegian review of international studies Screening for prostate cancer, Norwegian review of international studies Screening for prostate cancer, Norwegian review of international studies Norwegian Knowledge Centre for the Health Services Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Norwegian Knowledge (...) Centre for the Health Services. Screening for prostate cancer, Norwegian review of international studies. Norwegian Knowledge Centre for the Health Services (NOKC). SMM-Report 3/1999. 1999 Authors' objectives To evaluate the available documentation on screening for prostate cancer, as summarised in the INAHTA report 'Prostate Cancer Screening. Evidence Synthesis and Update'. Authors' conclusions The group of experts agree with the main conclusion from the INAHTA report; routine screening

Health Technology Assessment (HTA) Database.1999

8604. COX-2 inhibitors: a role in colorectal cancer?

COX-2 inhibitors: a role in colorectal cancer? COX-2 inhibitors: a role in colorectal cancer? COX-2 inhibitors: a role in colorectal cancer? Otten N Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Otten N. COX-2 inhibitors: a role in colorectal cancer? Ottawa: Canadian Coordinating Office for Health Technology Assessment/Office Canadien (...) de Coordination de l'Evaluation des Technologies de la Sante (CCOHTA) 1999: 4 Authors' objectives To summarise the available evidence on the use of COX-2 inhibitors in the treatment or prevention of colorectal cancer. Authors' conclusions The use of ASA or NSAIDs is not recommended for the prevention of colorectal cancer as there is insufficient high quality evidence of its benefit despite numerous epidemiological and laboratory studies. Project page URL Indexing Status Subject indexing assigned

Health Technology Assessment (HTA) Database.1999

8605. Photodynamic therapy for skin and mucosal cancer

Photodynamic therapy for skin and mucosal cancer Photodynamic therapy for skin and mucosal cancer Photodynamic therapy for skin and mucosal cancer Medical Services Advisory Committee Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Medical Services Advisory Committee. Photodynamic therapy for skin and mucosal cancer. Canberra: Medical (...) Services Advisory Committee (MSAC) 1999: 16 Authors' objectives This report summarises the assessment of current evidence for photodynamic therapy in the treatment of skin and mucosal cancer. Authors' conclusions Since there is currently insufficient evidence pertaining to photodynamic therapy, MSAC recommended that public funding should not be supported at this time for this procedure. Project page URL INAHTA brief and checklist Indexing Status Subject indexing assigned by CRD MeSH Mucous Membrane

Health Technology Assessment (HTA) Database.1999

8606. Prostate cancer screening: evidence synthesis and update (INAHTA Joint Project)

Prostate cancer screening: evidence synthesis and update (INAHTA Joint Project) Deteccion precoz del cancer de prostata (projecto INAHTA) Prostate cancer screening: evidence synthesis and update (INAHTA Joint Project) Deteccion precoz del cancer de prostata (projecto INAHTA) Prostate cancer screening: evidence synthesis and update (INAHTA Joint Project) Schersten T, Baile M A, Asua J, Jonsson E Citation Schersten T, Baile M A, Asua J, Jonsson E. Deteccion precoz del cancer de prostata (projecto (...) INAHTA). Prostate cancer screening: evidence synthesis and update (INAHTA Joint Project) Vitoria Gasteiz: Basque Office for Health Technology Assessment (OSTEBA). D-99-03. 1999 Authors' objectives

To summarize scientific evidence regarding the effectiveness and cost-effectiveness of mass screening for prostate cancer.

Authors' conclusions Mass screening for prostate cancer is not recommended because of lack of evidence regarding the benefits and the considerable risks of adverse effects

Health Technology Assessment (HTA) Database.1999

8607. Management of gynaecological cancers

Management of gynaecological cancers Management of gynaecological cancers Management of gynaecological cancers NHS Centre for Reviews and Dissemination Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation NHS Centre for Reviews and Dissemination. Management of gynaecological cancers. York: Centre for Reviews and Dissemination (CRD) 1999: 12 (...) Authors' objectives To summarise the management of the three most common gynaecological cancer: ovarian, endometrial and cervical cancer. Authors' conclusions The ovary, endometrium (uterus) and cervix are the fourth, fifth and sixth most common cancer sites after breast, lung and bowel in women in England and Wales. However, the average GP sees only one new patient with ovarian cancer about every five years, and patients with other gynaecological cancers even less frequently. Many women do

Health Technology Assessment (HTA) Database.1999

8608. Colorectal cancer screening

Colorectal cancer screening Colorectal cancer screening Colorectal cancer screening Conseil d'Evaluation des Technologies de la Sante Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Conseil d'Evaluation des Technologies de la Sante. Colorectal cancer screening. Montreal: Conseil d'Evaluation des Technologies de la Sante du Quebec (CETS (...) ). CETS 99-2 RE. 1999 Authors' objectives This report aims to review the epidemiology and carcinogenesis of colorectal cancer, then examine the evidence regarding the efficacy of different screening strategies both for precancerous lesions and malignant lesions that are still in their early stages. Authors' conclusions CETS believes that a colorectal cancer screening program would lead to a significant reduction in the mortality due to this type of cancer. Such a program would target asymptomatic

Health Technology Assessment (HTA) Database.1999

8609. Tamoxifen in treatment of intraductal breast cancer: National Surgical Adjuvant Breast and Bowel Project B-24 randomised controlled trial.

Tamoxifen in treatment of intraductal breast cancer: National Surgical Adjuvant Breast and Bowel Project B-24 randomised controlled trial. 10376613 1999 06 29 1999 06 29 2015 06 16 0140-6736 353 9169 1999 Jun 12 Lancet (London, England) Lancet Tamoxifen in treatment of intraductal breast cancer: National Surgical Adjuvant Breast and Bowel Project B-24 randomised controlled trial. 1993-2000 We have shown previously that lumpectomy with radiation therapy was more effective than lumpectomy alone (...) for the treatment of ductal carcinoma in situ (DCIS). We did a double-blind randomised controlled trial to find out whether lumpectomy, radiation therapy, and tamoxifen was of more benefit than lumpectomy and radiation therapy alone for DCIS. 1804 women with DCIS, including those whose resected sample margins were involved with tumour, were randomly assigned lumpectomy, radiation therapy (50 Gy), and placebo (n=902), or lumpectomy, radiation therapy, and tamoxifen (20 mg daily for 5 years, n=902). Median follow

Lancet1999

8610. The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation.

The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation. 10376571 1999 06 24 1999 06 24 2016 10 17 0098-7484 281 23 1999 Jun 16 JAMA JAMA The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation. 2189-97 Raloxifene hydrochloride is a selective estrogen receptor modulator that has antiestrogenic (...) effects on breast and endometrial tissue and estrogenic effects on bone, lipid metabolism, and blood clotting. To determine whether women taking raloxifene have a lower risk of invasive breast cancer. The Multiple Outcomes of Raloxifene Evaluation (MORE), a multicenter, randomized, double-blind trial, in which women taking raloxifene or placebo were followed up for a median of 40 months (SD, 3 years), from 1994 through 1998, at 180 clinical centers composed of community settings and medical practices

JAMA1999

8611. Comparison of radiation side-effects of conformal and conventional radiotherapy in prostate cancer: a randomised trial.

Comparison of radiation side-effects of conformal and conventional radiotherapy in prostate cancer: a randomised trial. 9929018 1999 02 09 1999 02 09 2015 06 16 0140-6736 353 9149 1999 Jan 23 Lancet (London, England) Lancet Comparison of radiation side-effects of conformal and conventional radiotherapy in prostate cancer: a randomised trial. 267-72 Radical radiotherapy is commonly used to treat localised prostate cancer. Late chronic side-effects limit the dose that can be given, and may (...) be linked to the volume of normal tissues irradiated. Conformal radiotherapy allows a smaller amount of rectum and bladder to be treated, by shaping the high-dose volume to the prostate. We assessed the ability of this new technology to lessen the risk of radiation-related effects in a randomised controlled trial of conformal versus conventional radiotherapy. We recruited men with prostate cancer for treatment with a standard dose of 64 Gy in daily 2 Gy fractions. The men were randomly assigned

Lancet1999

8612. Lack of effect of coumarin in women with lymphedema after treatment for breast cancer.

Lack of effect of coumarin in women with lymphedema after treatment for breast cancer. 9929524 1999 02 09 1999 02 09 2012 11 15 0028-4793 340 5 1999 Feb 04 The New England journal of medicine N. Engl. J. Med. Lack of effect of coumarin in women with lymphedema after treatment for breast cancer. 346-50 Lymphedema of the arms can be a serious consequence of local and regional therapy in women with breast cancer. Coumarin has been reported to be effective for the treatment of women with lymphedema (...) ; we undertook a study in which we attempted to replicate those findings. We studied 140 women with chronic lymphedema of the ipsilateral arm after treatment for breast cancer. The women received 200 mg of oral coumarin or placebo twice daily for six months and then the other treatment for the following six months. The end points of the study consisted of the volume of the arm (calculated from measurements of hand and arm circumference) and the answers on a questionnaire completed by the patient

NEJM1999

8613. Postoperative radiotherapy in high-risk postmenopausal breast-cancer patients given adjuvant tamoxifen: Danish Breast Cancer Cooperative Group DBCG 82c randomised trial.

Postoperative radiotherapy in high-risk postmenopausal breast-cancer patients given adjuvant tamoxifen: Danish Breast Cancer Cooperative Group DBCG 82c randomised trial. 10335782 1999 06 10 1999 06 10 2015 06 16 0140-6736 353 9165 1999 May 15 Lancet (London, England) Lancet Postoperative radiotherapy in high-risk postmenopausal breast-cancer patients given adjuvant tamoxifen: Danish Breast Cancer Cooperative Group DBCG 82c randomised trial. 1641-8 Postmastectomy radiotherapy is associated (...) with a lower locoregional recurrence rate and improved disease-free and overall survival when combined with chemotherapy in premenopausal high-risk breast-cancer patients. However, whether the same benefits apply also in postmenopausal women treated with adjuvant tamoxifen for similar high-risk cancer is unclear. In a randomised trial among postmenopausal women who had undergone mastectomy, we compared adjuvant tamoxifen alone with tamoxifen plus postoperative radiotherapy. Between 1982 and 1990

Lancet1999

8614. Role of immunohistochemical detection of lymph-node metastases in management of breast cancer. International Breast Cancer Study Group.

Role of immunohistochemical detection of lymph-node metastases in management of breast cancer. International Breast Cancer Study Group. 10489948 1999 09 28 1999 09 28 2015 11 19 0140-6736 354 9182 1999 Sep 11 Lancet (London, England) Lancet Role of immunohistochemical detection of lymph-node metastases in management of breast cancer. International Breast Cancer Study Group. 896-900 This study was designed to ascertain whether immunohistochemical methods could improve the detection of metastases (...) in primary breast-cancer patients whose axillary lymph nodes were classified, by conventional methods, as disease free. Ipsilateral lymph nodes (negative for metastases by routine histology) from 736 patients (participants in Trial V of the International [Ludwig] Breast Cancer Study) were examined by serial sectioning and staining with haematoxylin and eosin (two sections from each of six levels) and by immunohistochemistry of a single section (with two anticytokeratins AE-1 and CAM 5.2). After median

Lancet1999

8615. Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer.

Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer. 10588962 1999 12 10 1999 12 10 2013 11 21 0028-4793 341 24 1999 Dec 09 The New England journal of medicine N. Engl. J. Med. Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer. 1781-8 Because the optimal timing of the institution of antiandrogen (...) therapy for prostate cancer is controversial, we compared immediate and delayed treatment in patients who had minimal residual disease after radical prostatectomy. Ninety-eight men who underwent radical prostatectomy and pelvic lymphadenectomy and who were found to have nodal metastases were randomly assigned to receive immediate antiandrogen therapy, with either goserelin, a synthetic agonist of gonadotropin-releasing hormone, or bilateral orchiectomy, or to be followed until disease progression

NEJM1999

8616. Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide.

Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide. 9920950 1999 02 02 1999 02 02 2013 11 21 0028-4793 340 4 1999 Jan 28 The New England journal of medicine N. Engl. J. Med. Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide. 265-71 For small-cell lung cancer confined to one hemithorax (limited small-cell lung (...) cancer), thoracic radiotherapy improves survival, but the best ways of integrating chemotherapy and thoracic radiotherapy remain unsettled. Twice-daily accelerated thoracic radiotherapy has potential advantages over once-daily radiotherapy. We studied 417 patients with limited small-cell lung cancer. All the patients received four 21-day cycles of cisplatin plus etoposide. We randomly assigned these patients to receive a total of 45 Gy of concurrent thoracic radiotherapy, given either twice daily

NEJM1999

8617. Screening for ovarian cancer: a pilot randomised controlled trial.

Screening for ovarian cancer: a pilot randomised controlled trial. 10217079 1999 05 13 1999 05 13 2016 11 24 0140-6736 353 9160 1999 Apr 10 Lancet (London, England) Lancet Screening for ovarian cancer: a pilot randomised controlled trial. 1207-10 The value of screening for ovarian cancer is uncertain. We did a pilot randomised trial to assess multimodal screening with sequential CA 125 antigen and ultrasonography. Postmenopausal women aged 45 years or older were randomised to a control group (n (...) =10,977) or screened group (n=10,958). Women randomised to screening were offered three annual screens that involved measurement of serum CA 125, pelvic ultrasonography if CA 125 was 30 U/mL or more, and referral for gynaecological opinion if ovarian volume was 8.8 mL or more on ultrasonography. All women were followed up to see whether they developed invasive epithelial cancers of the ovary or fallopian tube (index cancers). Of 468 women in the screened group with a raised CA 125, 29 were referred

Lancet1999

8618. Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer.

Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer. 10202164 1999 04 15 1999 04 15 2013 11 21 0028-4793 340 15 1999 Apr 15 The New England journal of medicine N. Engl. J. Med. Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer. 1137-43 We compared the effect of radiotherapy to a pelvic and para-aortic field with that of pelvic radiation and concurrent (...) chemotherapy with fluorouracil and cisplatin in women with advanced cervical cancer. Between 1990 and 1997, 403 women with advanced cervical cancer confined to the pelvis (stages IIB through IVA or stage IB or IIa with a tumor diameter of at least 5 cm or involvement of pelvic lymph nodes) were randomly assigned to receive either 45 Gy of radiation to the pelvis and para-aortic lymph nodes or 45 Gy of radiation to the pelvis alone plus two cycles of fluorouracil and cisplatin (days 1 through 5 and days 22

NEJM1999

8619. Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer.

Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer. 10202165 1999 04 15 1999 04 15 2013 11 21 0028-4793 340 15 1999 Apr 15 The New England journal of medicine N. Engl. J. Med. Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer. 1144-53 On behalf of the Gynecologic Oncology Group, we performed a randomized trial of radiotherapy in combination with three concurrent chemotherapy regimens -- cisplatin alone (...) ; cisplatin, fluorouracil, and hydroxyurea; and hydroxyurea alone -- in patients with locally advanced cervical cancer. Women with primary untreated invasive squamous-cell carcinoma, adenosquamous carcinoma, or adenocarcinoma of the cervix of stage IIB, III, or IVA, without involvement of the para-aortic lymph nodes, were enrolled. The patients had to have a leukocyte count of at least 3000 per cubic millimeter, a platelet count of at least 100,000 per cubic millimeter, a serum creatinine level no higher

NEJM1999

8620. Extended lymph-node dissection for gastric cancer.

Extended lymph-node dissection for gastric cancer. 10089184 1999 03 25 1999 03 25 2006 11 15 0028-4793 340 12 1999 Mar 25 The New England journal of medicine N. Engl. J. Med. Extended lymph-node dissection for gastric cancer. 908-14 Curative resection is the treatment of choice for gastric cancer, but it is unclear whether this operation should include an extended (D2) lymph-node dissection, as recommended by the Japanese medical community, or a limited (D1) dissection. We conducted (...) a randomized trial in 80 Dutch hospitals in which we compared D1 with D2 lymph-node dissection for gastric cancer in terms of morbidity, postoperative mortality, long-term survival, and cumulative risk of relapse after surgery. Between August 1989 and July 1993, a total of 996 patients entered the study. Of these patients, 711 (380 in the D1 group and 331 in the D2 group) underwent the randomly assigned treatment with curative intent, and 285 received palliative treatment. The procedures for quality

NEJM1999